PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gainers
HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million.
PDS Biotechnology (NASDAQ:PDSB) shares movedread more...
PDS Biotech (NASDAQ:PDSB) is entering a potentially pivotal stretch with fresh capital, a high-profile new board member and a sharply narrowed clinical strategy centered on its PDS0301 immunocytokine.
Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing agreement.read more...
Gainers
PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million.
DataMEDS AI (NASDAQ:MEDS) shares increased byread more...
PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.